

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of ~~diagnosing~~ screening cancer in a test mammal for cancer comprising assaying for the level of zinc α -2-glycoprotein (ZAG) present in a ~~biological serum~~ sample from said test mammal and comparing that level to ~~a biological~~ the level of ZAG present in a serum sample from a control, non-tumor bearing mammal, wherein said test mammal and said control mammal are of the same species and the ZAG level in the serum samples from the test mammal and the control mammal are assayed using the same technique, and wherein an elevated level of ZAG in the ~~biological serum~~ sample from said test mammal relative to said control is indicative of the presence of ~~a tumor~~ cancer.

Claims 2 and 3 (Cancel).

4. (Original) The method according to claim 1 wherein the level of ZAG is assayed using an immunoassay, chromatography, electrophoresis, or solid phase affinity or densitometry of a Western blot.

5. (Original) The method according to claim 4 wherein the level of ZAG is assayed using an antigen capture or competitive immunoassay.

6. (Currently Amended) The method according to claim 1 wherein said test mammal is suspected of having ~~method is a method of diagnosing~~ prostate cancer.

Claim 7 (Cancel).

8. (Withdrawn) A method of diagnosing an inflammatory disease or disorder in a test mammal comprising assaying for the level of zinc α -2-glycoprotein (ZAG) present in a biological sample from said test mammal and comparing that level to a biological sample from a control mammal, wherein an elevated level of ZAG in the biological sample from said test mammal relative to said control is indicative of the presence of an inflammatory disease or disorder.

9. (Withdrawn) The method according to claim 8 wherein said biological sample is a liquid sample.

10. (Withdrawn) The method according to claim 9 wherein said biological sample is a serum sample.

11. (Withdrawn) The method according to claim 8 wherein the level of ZAG is assayed using an immunoassay, chromatography, electrophoresis, or solid phase affinity or densitometry of a Western blot.

12. (Withdrawn) The method according to claim 11 wherein the level of ZAG is assayed using an antigen capture or competitive immunoassay.

13. (Withdrawn) The method according to claim 8 wherein said inflammation is of the breast, prostate, liver, or salivary, bronchial, gastrointestinal or sweat gland of said mammal.

14. (Withdrawn) A method of inhibiting thymic atrophy in a mammal comprising administering to said mammal an amount of an agent that reduces the bioavailability of ZAG or that inhibits the binding of ZAG to its receptor sufficient to effect said inhibition of atrophy.

15. (Withdrawn) The method according to claim 14 wherein said mammal is an adult bearing a tumor.

16. (Withdrawn) The method according to claim 15 wherein said mammal is undergoing cancer chemotherapy.

17. (Withdrawn) The method according to claim 14 wherein said mammal has an infection.

18. (Withdrawn) The method according to claim 17 wherein said infection is an HIV infection.

19. (Withdrawn) The method according to claim 14 wherein said agent is an anti-ZAG antibody or an antiandrogen.